Nanoengineered therapeutic strategies targeting SNHG1 for mitigating microglial ischemia-reperfusion injury implications for hypoxic-ischemic encephalopathy

• Published in: SLAS technology Vol. 29; no. 4; p. 100167
• Main Authors: Bao, Li, Chen, Mingzhi, Dai, Biao, Lei, Yong, Qin, Dani, Cheng, Mengke, Song, Wei, He, Wenxia, Chen, Bingyu, Shen, Huiping
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2024; Elsevier
• Subjects: Apoptosis; bv2; Drug; Nanoengineering; Small Nucleolar RNA Host Gene(SNHG); Drug; Small Nucleolar RNA Host Gene(SNHG); bv2; Apoptosis; Nanoengineering
• ISSN: 2472-6303; 2472-6311; 2472-6311
• DOI: 10.1016/j.slast.2024.100167

The purpose of this work is to investigate the function of SNHG1, a long non-coding RNA implicated in disease progression, apoptosis, and proliferation, in order to solve the problem of hypoxic-ischemic encephalopathy (HIE) in newborn care. We investigated the impact of overexpressing SNHG1 on hypoxia-induced apoptosis and studied its expression in BV2 microglial cells under hypoxic circumstances. As a result of modifying YY1 expression, SNHG1′s overexpression prevents apoptosis, as our data demonstrate that it is considerably downregulated under hypoxia. We demonstrate that SNHG1 might potentially reduce microglial ischemia-reperfusion damage by using sophisticated nanoengineering drug delivery technologies to target it. This provides encouraging information for the therapy of ischemic epilepsy.